Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ECO
    --Site Admin--
    • Oct 2007
    • 1360

    #1

    Fancy a peek inside Sanger's Illumina GA Pipeline?



    So it has been brought to my attention that the Sanger has a publicly accessible "stats" page that contains quite a few statistics about their Illumina short read pipeline. The stats give a very interesting look into the daily operations of perhaps the highest throughput genome center in the world (...if I had a nickel for every PM I will get correcting me! ).

    Screenshot of the public page, containing a dropdown menu for different stats:


    I have reproduced all the available data below, unchanged (with the exception of blanking out someone's email address) as of this evening. I am hesitant to post the URL only because I don't want to cause undue ruckus, or cost anyone their job. I know these big genome centers are fiercely competitive...

    With that. Enjoy.











































    Eighty percent of the 28 genome analyzers that they have translates to 22 of them running all the time!


    Just scanned through Google Analytics, and realized that Sanger sends a fair amount of traffic here...appears they have a link to a popular thread on their intranet! Greetings Sanger-folk!
  • cgb
    Member
    • May 2008
    • 50

    #2
    Graphs

    I see our graphs are getting around.

    Couple of things not clear from them as shown.

    The yields are PF yields, i.e from non-overlapping clusters. typically this is half of all of the clusters on a dense chip. Some people quote yields as total bases.

    Per run numbers are used, for paired end runs - which are about 90% - two runs needs to be summed to give yield per flowcell.

    Error rates are estimated fro control lanes and very often are an average of first and second read rates for a flowcell with 2 runs. Second reads often have worse data quality that first (this is being fixed in collaboration with illumina). Early data is clearly from a very small number of runs with high variable success rates - hence the mountains - error bars are not on these graphs but the would be very broad for early data, and very narrow for later data.

    Some of the graphs are under development.

    c.

    Comment

    • cgb
      Member
      • May 2008
      • 50

      #3
      http://www.genomeweb.com/issues/news/146798-1.html

      in fact this article is a little off, the 300 Gigabases already submitted is bigger than Genbank.

      Comment

      • cgb
        Member
        • May 2008
        • 50

        #4
        a new page is coming fro Roger....

        Comment

        • cgb
          Member
          • May 2008
          • 50

          #5
          I'm sorry, your page cannot be found on this site.

          Comment

          • cgb
            Member
            • May 2008
            • 50

            #6
            I think Sanger will hit 1 Terabase (PF) by the end of june

            Comment

            • cgb
              Member
              • May 2008
              • 50

              #7
              ta daaaaa

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
                by SEQadmin2




                NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
                Today, 06:46 AM
              • SEQadmin2
                Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
                by SEQadmin2



                Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

                Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
                ...
                10-14-2026, 09:55 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, 10-28-2026, 09:57 AM
              0 responses
              22 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-28-2026, 09:51 AM
              0 responses
              14 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-22-2026, 11:13 AM
              0 responses
              67 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 10-22-2026, 10:48 AM
              0 responses
              47 views
              0 reactions
              Last Post SEQadmin2  
              Working...